Paul R. Kirchgraber - 30 Mar 2023 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role: CEO, Covance Drug Development
Signature: /s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Issuer symbol: LH
Transactions as of: 30 Mar 2023
Net transactions value: -$648,484
Form type: 4
Filing time: 03 Apr 2023, 10:13:05 UTC
Previous filing: 23 Feb 2023
Next filing: 23 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LH	Common Stock	Award	$0	+6,763	+75%	$0.000000	15,832	30 Mar 2023	Direct	F1
transaction	LH	Common Stock	Tax liability	$648,484	-2,886	-18%	$224.70	12,946	30 Mar 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022.
F2	Stock withholding to satisfy tax withholding obligations.